An interventional study of Exercise and Heat Therapy in Elevated Blood Pressure, sponsored by Providence College. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-01.
Sponsored by Providence College · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,032 studies in Hypertension with a site in United States — 268 open to participants now, 369 under way, 16 of them phase 3. Hypertension · United States.
Among the 2,032 studies in Hypertension with a site in United States, this one is the 1,502nd largest by enrollment of the 1,780 interventional ones that give a count, is one of 93 that started in 2024, is one of 1,072 with no phase, and was the 1,776th registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →268 of the 2,032 studies in Hypertension with a site in United States are open now. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+
University of Alabama at Birmingham · Sites in United States
Ages 16–56 · Women only
The University of Texas at Arlington · Sites in United States
Ages 26–49
CRISPR Therapeutics AG · Sites in United States, Australia, United Kingdom
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,032 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 147 · Phase 2 216 · Phase 3 214 · Phase 4 188
First in 1973; this study’s year is marked. 93 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 100 across the 1,780 interventional studies, 200 across the 238 observational. Of the 1,515 that completed or were terminated, 578 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
461 of 2,032 have an industry lead sponsor. The 10 most frequent:
Providence College is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Providence College has 1 study filed under Hypertension — fewer than ten, so there is no comparison to draw.
144 of the studies in Hypertension with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT04971720Phase 3University of Alabama at BirminghamPRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis | 2027-01-01 |
| NCT06948422Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) | 2027-09 |
| NCT06948435Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | 2027-09 |
| NCT06952530Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 | 2027-09 |
Add all 144 to your calendar (.ics) → With an account.
Among the 2,032 studies in Hypertension with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to test whether putting a participant's legs in a hot bath after exercise improves blood pressure in people with higher blood pressure.
. The main questions it aims to answer are:
Participants will complete four different trials:
In 2017, the American Heart Association updated standards for diagnosing hypertension, while emphasizing the need for lifestyle modification in the early stages of blood pressure elevation. Using these updated criteria, approximately 1/3 of U.S. adults have hypertension, but few are able to improve blood pressure through diet and exercise and often progress to more severe disease states. Novel interventions to promote blood pressure reduction in mild hypertension are needed to attenuate or prevent this progression to more severe hypertension. Heat therapy, the repeated application of passive heat through hot water immersion, has gained recent attention for promising blood pressure reduction and improvement in cardiovascular health. Preliminary work combining exercise and hot water leg immersion indicates improved overnight blood pressure in individuals with elevated blood pressure, but the magnitude and mechanisms of this improvement require further study.
It is unknown whether the decrease in blood pressure following post-exercise heat exposure results from changes in systemic regulation (autonomic nervous system function, measured through heart rate variability), local factors (improved blood vessel function, measured through flow-mediated dilation), or both. The goal of the proposed research is to examine the impact of exercise alone (30 minutes of treadmill walking), hot water immersion alone (45 minutes in a leg bath set to 42°C), and combined exercise + hot water immersion (30 minutes treadmill walking followed by 45 minutes in a 42°C leg bath) on nocturnal blood pressure, autonomic function, and blood vessel function in individuals with elevated blood pressure. This goal will be addressed with the following specific aims:
Aim 1. To examine the impact of exercise, hot water leg immersion, or combined exercise + hot water immersion on overnight blood pressure in individuals with elevated blood pressure. The researchers hypothesize that the combination of exercise and hot water immersion will result in reduced systolic and diastolic blood pressure through 12 hours post-exercise as compared to baseline or either standalone treatment.
Aim 2. To examine changes in autonomic function, as measured by heart rate variability (HRV) following exercise, leg heating, or combined therapies. The researchers hypothesize that combined exercise and hot water immersion will result in higher HRV (indicating improved autonomic balance) compared to baseline measures.
Aim 3. To examine changes in blood vessel (endothelial) function, measured using flow-mediated dilation, following exercise, leg heating, or combined therapies. The researchers hypothesize that combined exercise and hot water immersion will result in a higher flow-mediated dilation (indicating improved blood vessel relaxation) compared to baseline or either standalone intervention.
The results of this study have important health implications in the treatment of hypertension using lifestyle interventions for the millions of Americans with elevated blood pressure or hypertension. The findings have the potential to improve non-pharmacological treatment of hypertension by developing an exercise and heat exposure protocol that is cost-effective, easily implemented, and results in substantially reduced blood pressure and improved cardiovascular risk profile.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This treatment will include exercise (treadmill walking) and hot leg bath.
Behavioral: Exercise · Other: Heat Therapy
This treatment will only include the hot leg bath (no exercise).
Other: Heat Therapy
This treatment will include exercise (treadmill walking) followed by a sham leg bath.
Behavioral: Exercise · Other: Sham leg bath
Participants will refrain from exercise or heat exposure for at least 24 hours, and perform all study analyses for a control comparison.
Participants will walk on a treadmill for 30 minutes at 55-60% of heart rate reserve. The treadmill will be set at 2mph and 2% grade, then be adjusted in the first 5 minutes to achieve target heart rate.
Also known as: Treadmill walking
Participants will place their legs in a deep leg bath (mid-calf) set to 42C for 45 minutes.
Also known as: hot leg bath
Participants will place their legs in a deep leg bath (mid-calf) set to 36C for 45 minutes.
Also known as: lukewarm leg bath
Ambulatory blood pressure
Welch-Allyn ambulatory blood pressure monitor placed on the arm after treatment
Time frame: 24 hours post-treatment
Heart Rate Variability
3-lead ECG with paced breathing measured post-treatment
Time frame: 30-60 min post-treatment
Flow-mediated dilation
Measure of endothelial function in the brachial artery (arm), change in blood vessel diameter following a 5-minute blood flow occlusion and release
Time frame: 30-60 min post-treatment
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — The current plan is to share only compiled data with other researchers if requested.
Ran from Jul 2024 to primary completion in Apr 2026, 21 months.
Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 21 months is close to that.
Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Providence College